1-[4-(Pyridin-4-yl)piperazin-1-yl]ethan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[4-(Pyridin-4-yl)piperazin-1-yl]ethan-1-one
• 英文别名: 1-(4-pyridin-4-ylpiperazin-1-yl)ethanone
• 化学式: C₁₁H₁₅N₃O
• mdl: MFCD00956647
• 分子量: 205.26
• InChiKey: DUIMATYBNXNRMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  36.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• Nitrogen-containing heterocyclic compound
  申请人：Murakata Chikara

  公开号：US20090054407A1

  公开（公告）日：2009-02-26

  The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): wherein W represents a nitrogen atom or —CH—; X represents —C(═O)— or —CHR 4 — (wherein R 4 represents a hydrogen atom, or the like); R 1 represents a group represented by the following formula: [wherein Q 1 represents a nitrogen atom or —CR 8 — (wherein R 8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q 2 represents —NR 15 — (wherein R 15 represents a hydrogen atom, or the like) and R 5 and R 6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R 2 and R 3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种含氮杂环化合物，其由式(I)表示：其中W代表氮原子或—CH—；X代表—C(═O)—或—CHR4—（其中R4代表氢原子或类似物）；R1代表由以下式表示的基团：[其中Q1代表氮原子或—CR8—（其中R8代表氢原子、取代或未取代的低级烷基或类似物）。Q2代表—NR15—（其中R15代表氢原子或类似物），R5和R6可以相同也可以不同，每个代表氢原子、取代或未取代的低级烷基或类似物]；R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的低级烷基或类似物}或其药学上可接受的盐等。
• PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF
  申请人：Ebiike Hirosato

  公开号：US20100324284A1

  公开（公告）日：2010-12-23

  A preventive or therapeutic agent of a proliferative disease such as cancer, having superior PI3K inhibitory effects, superior cell proliferation inhibitory action as well as superior stability in a body and water solubility, is provided. A compound represented by formula (I): [wherein, Q represents a linking group represented by —X—Y—; X represents a single bond —CO—, —CONH—, —CON(C 1-4 alkyl)-, —CS—, —CSNH—, —CSN(C 1-4 alkyl)-, or —SO 2 —; Y represents a single bond, arylene or heteroarylene; provided that X and Y are not simultaneously single bonds; and R 1 represents —C 0-6 alkylene-(A) m -C 1-6 alkyl, or C 0-6 alkylene-(A) m -C 0-6 alkylene-(heterocycle)] or a pharmaceutically acceptable salt thereof.

  提供了一种预防或治疗增殖性疾病（如癌症）的药物，具有优越的PI3K抑制作用、优越的细胞增殖抑制作用以及在体内具有优越的稳定性和水溶性。该化合物的式子为（I）：[其中，Q表示由—X—Y—表示的连接基；X表示单键—CO—、—CONH—、—CON（C1-4烷基）-、—CS—、—CSNH—、—CSN（C1-4烷基）-或—SO2—；Y表示单键、芳基或杂芳基；但X和Y不能同时为单键；R1表示—C0-6烷基-(A)m-C1-6烷基，或C0-6烷基-(A)m-C0-6烷基-(杂环)]或其药学上可接受的盐。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1880993A1

  公开（公告）日：2008-01-23

  The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): wherein W represents a nitrogen atom or -CH-; X represents -C(=O)- or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or -CR8- (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), Q2 represents -NR15- (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like } or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由式（I）表示的含氮杂环化合物： 其中 W 代表氮原子或-CH-； X代表-C(＝O)-或-CHR4-（其中R4代表氢原子或类似物）； R1 代表下式所代表的基团： [其中 Q1 代表氮原子或-CR8-（其中 R8 代表氢原子、取代或未取代的低级烷基或类似物），Q2 代表-NR15-（其中 R15 代表氢原子或类似物），R5 和 R6 可以相同或不同，各自代表氢原子、取代或未取代的低级烷基或类似物]；以及 R2 和 R3 可以相同或不同，各自代表氢原子、卤素、取代或未取代的低级烷基或类似物 } 或其药学上可接受的盐等。